|
| Status |
Public on Jul 21, 2017 |
| Title |
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation(s) |
28805822 |
| |
| Submission date |
Oct 18, 2016 |
| Last update date |
Jul 25, 2021 |
| Contact name |
Zhenqing Ye |
| E-mail(s) |
[email protected]
|
| Organization name |
UT Health San Antonio
|
| Department |
6Department of Population Health Sciences
|
| Street address |
8403 Floyd Curl Dr
|
| City |
San Antonio |
| State/province |
TX |
| ZIP/Postal code |
78229 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
| Samples (26)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE78213 |
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer (BRD4_JQ1_RNA-seq) |
| GSE88871 |
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer (ChIP-Seq) |
| GSE98010 |
SPOP mutation confers intrinsic BET inhibitor resistance in prostate cancer (BRDs_OE_RNA-seq) |
|
| Relations |
| BioProject |
PRJNA348842 |
Less...
More...